Streptococcus milleri group

(redirected from Streptococcus anginosus group)

Strep·to·coc·cus mil·ler·i group

(strep'tō-kok'ŭs mil'ler-ī grūp)
A term used to refer to the Streptococcus intermedius group, which contains three distinct streptococcal species: S. intermedius, S. constellatus, and S. anginosus. These bacteria are found in the human oral cavity and have been associated with a variety of infections including bacteremia, endocarditis, and central nervous system, oral, and thoracic infections.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012
References in periodicals archive ?
Identification of the 'Streptococcus anginosus group' by matrix-assisted laser desorption ionization--time-of-flight mass spectrometry.
Clinical and microbiological outcomes in patients with Streptococcus anginosus group bacteraemia identified through use of a rapid microarray assay.
Subjects with CLP presented with all members of the Streptococcus anginosus group (i.e., S.
Streptococcus anginosus group (SAG), previously described as the S.
Abbreviations ALT: Alanine aminotransferase AST: Aspartate aminotransferase CRP: C-reactive protein ESR: Erythrocyte sedimentation rate INR: International normalized ratio SAG: Streptococcus anginosus group. 10.1155/2017/5864694
Streptococcus intermedius was the cause of the osteomyelitis in the patient described here; this bacterial strain belongs to the Streptococcus anginosus group. This group is recognized as consisting of commensal bacteria of the oral cavity and the gastrointestinal and urogenital tracts but is also known for abscess formation in various locations in the body and for infective endocarditis [12].
constellatus form the "Streptococcus anginosus group," has recently been associated with carcinogenesis in the aerodigestive tract.
Dalbavancin and Oritavancin are IV-only lipoglycopeptides indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates for the treatment of ABSSI caused by Gram-positive microorganisms such as methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus anginosus group. They act via interfering in the synthesis of bacterial cell wall by inhibiting the synthesis of peptidoglycan layer or by disrupting the bacterial membrane integrity, leading to depolarization, increased permeability and cell death.
Genotyping by amplified fragment length polymorphism analysis reveals persistence and recurrence of infection with Streptococcus anginosus group organisms.
VIBATIV (telavancin) is approved in the US and in Canada for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includes S.
The proposed indication for telavancin is for the treatment of complicated skin and skin structure infections (cSSSI) caused by Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, the Streptococcus anginosus group, and Enterococcus faecalis.